aibio
Financings ·
Marker Therapeutics signs $16.1 million private placement
Investors agreed to buy 1,783,805 shares plus warrants. The warrants need stockholder approval before they can be exercised.
MRKR Marker Therapeutics, Inc.
Marker Therapeutics (MRKR) news MRKR offering news
Latest Marker Therapeutics news
We have not published a story on Marker Therapeutics yet. When there is news, it will appear here.
What Marker Therapeutics does
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing T cell-based immunotherapies for hematological malignancies and solid tumors. Its Multi Antigen Recognizing, or MAR-T, cell technology selectively expands natural tumor-specific T cells from a patient's or donor's blood without genetic modification, and the company says these cells recognize a broad range of tumor-associated antigens. The company licensed the underlying technology from Baylor College of Medicine in March 2018, and BCM used it in seven exploratory clinical trials. The lead autologous product, MT-601, is in a Phase 1 APOLLO study in relapsed lymphoma patients who failed or are ineligible for anti-CD19 CAR-T therapy, and the study has advanced to dose expansion. MT-601 is also in a Phase 1 PANACEA trial for locally advanced, unresectable or metastatic pancreatic cancer in combination with front-line chemotherapy. The FDA granted orphan drug designation to MT-601 for pancreatic cancer in January 2022. An off-the-shelf product, MT-401-OTS, is in the Phase 1 RAPID study for acute myeloid leukemia or myelodysplastic syndromes. The company's pancreatic program is supported by a grant from the Cancer Prevention and Research Institute of Texas and a grant from the NIH Small Business Innovation Research program.
| Product or program | What it is | Stage |
|---|---|---|
| MT-601 (autologous) | MAR-T cell product for relapsed lymphoma after anti-CD19 CAR-T therapy | Phase 1 APOLLO study, advanced to dose expansion |
| MT-601 in pancreatic cancer | MAR-T cells combined with front-line chemotherapy for metastatic pancreatic cancer | Phase 1 PANACEA study |
| MT-401-OTS | Off-the-shelf MAR-T cell product for acute myeloid leukemia or myelodysplastic syndromes | Phase 1 RAPID study |
Marker Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $11.8 million | $13.5 million |
| Net income (loss) | -$12.2 million | -$10.7 million |
| Cash from operations | -$12.0 million | -$10.9 million |
| Cash and equivalents | $16.1 million | $19.2 million |
Questions about Marker Therapeutics
Has Marker Therapeutics raised money recently?
Our latest story on this, dated Dec 19, 2024: "Marker Therapeutics signs $16.1 million private placement". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Marker Therapeutics?
Marker Therapeutics, Inc. trades under the ticker MRKR on NASDAQ.
Where is Marker Therapeutics listed?
Marker Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:GX1.
What is the SEC CIK of Marker Therapeutics?
The SEC Central Index Key (CIK) for Marker Therapeutics, Inc. is 1094038. Its filings are on SEC EDGAR.
How many shares does Marker Therapeutics have outstanding?
16,673,127 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-14.
Which country or territory is Marker Therapeutics listed under?
Our directory records Marker Therapeutics, Inc. under United States.
What does Marker Therapeutics do?
Our directory classifies Marker Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Marker Therapeutics?
The ISIN recorded for Marker Therapeutics, Inc. is US57055L2060.
Does aibio.space cover Marker Therapeutics?
aibio.space lists Marker Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Marker Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What does Marker Therapeutics develop?
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing T cell-based immunotherapies for hematological malignancies and solid tumors. Its Multi Antigen Recognizing, or MAR-T, cell technology selectively expands natural tumor-specific T cells from a patient's or donor's blood without genetic modification, and the company says these cells recognize a broad range of tumor-associated antigens.
What is MT-601 (autologous) from Marker Therapeutics?
MT-601 (autologous): MAR-T cell product for relapsed lymphoma after anti-CD19 CAR-T therapy Stage: Phase 1 APOLLO study, advanced to dose expansion.
What is MT-601 in pancreatic cancer from Marker Therapeutics?
MT-601 in pancreatic cancer: MAR-T cells combined with front-line chemotherapy for metastatic pancreatic cancer Stage: Phase 1 PANACEA study.
Is Marker Therapeutics profitable?
Marker Therapeutics, Inc. reported a net loss of $12.2 million for the fiscal year ended Dec 31, 2025, and used $12.0 million of cash in operations, per its annual report to the SEC.
How much does Marker Therapeutics spend on research and development?
$11.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
Investor discussion: Marker Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
- Financings
Filed a final prospectus for a securities offering. SEC Form 424B7. Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Stock chart
SEC filings and registration
- SEC name
- Marker Therapeutics, Inc.
- CIK
- 1094038
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- MRKR (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 2450 HOLCOMBE BLVD, HOUSTON, TX, 77021
- Phone
- (713) 400-6400
- Shares outstanding
- 16,673,127 as of 2026-08-07 (10-Q filed 2026-08-14)
- Former names
- TAPIMMUNE INC.; TAPIMMUNE INC; GENEMAX CORP
Recent filings
Listing details
- Company
- Marker Therapeutics, Inc.
- Ticker
- MRKR
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US57055L2060
- Other listed symbols
- GETTEX:GX1
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction